Vodis Pharmaceuticals Inc. (CSE:VP,FSE:1JV1) has entered the confirmation of readiness stage to become a licenced producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR) at its Delta, B.C., facility. The Confirmation of Readiness stage is the final stage before obtaining a licence from Health Canada to cultivate cannabis under the ACMPR.

As previously announced, Vodis undertook upgrades to its Delta facility. These upgrades included the installation of specialized wall finishes in the production and processing areas, upgraded Ceramic Metal Halide and LED lighting, installation of Ample Organics software for seed-to-sale tracking, and upgrades to the internal physical security of the facility. The Company is completing these upgrades and plans to file a comprehensive Confirmation of Readiness evidence package with Health Canada in the coming weeks.


Vodis’ CEO, Ivan Miliovski, states: “This is an important milestone that gets us closer to obtaining a cultivation licence at our Delta facility. We are very excited about the path forward and creating the shareholder value that we set out to achieve.”

The passing of the Cannabis Act has dramatically expanded the Canadian cannabis market. While Vodis intends to sell into the various provincial recreational markets, the Company remains committed to the many Canadians that have expressed interest in purchasing high-quality Vodis product for medical purposes. The Company encourages future patients to join our email mailing list at https://vodis.ca. The Company is also continuing its brand and future-patient outreach efforts at the Grow Up Cannabis Conference and Expo in Niagara Falls, Ontario, on September 7-8, 2018.

About Vodis Pharmaceuticals Inc.

Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.

While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State licence holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed Vodis-brand quality standards.

Click here to connect with Vodis Pharmaceuticals Inc. (CSE:VP,FSE:1JV1)  for an Investor Presentation. 

Source: www.stockwatch.com

Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that, in connection with the previously announced share consolidation on a thirty (30) for one (1) basis (the “Consolidation”), the Company will be changing its name to West Island Brands Inc. (the “Name Change”).

The common shares are scheduled to begin trading on a post-consolidation basis at market open on October 20, 2021 under the stock symbol “WIB”. The new CUSIP number will be 953400108 and the new ISIN number will be CA9534001081. Following the Consolidation, the Company will have approximately 10,712,484 common shares issued and outstanding.

Keep reading... Show less

In the cannabis space this week, a popular beverage maker hired a new executive in hopes of pursuing opportunities in the cannabis drink industry.

Meanwhile, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced a fresh acquisition agreement for a partner designed to boost its presence in a potentially available US adult-use cannabis market.

Keep reading... Show less

Via InvestorWireIBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announces that it will be collaborating with Microdose Psychedelic Insights for the Psych e delic Capital: October 2021 Conference which is set to be held in an entirely virtual format on Oct. 28, 2021.

The Psychedelic Capital: October Conference is set to be a virtual event, covering the most innovative and cutting-edge companies, latest IPOs, newest opportunities and deepest insights into the global psychedelic industry. From exploring ongoing governmental policy shifts to commercial product breakthroughs, the conference will serve to educate attendees on the potential uses and benefits attached to psychedelics in today’s environment.

Keep reading... Show less

 Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (“Adastra” or the “Company”) today announced positive operational and financial developments as the Company continues to pursue its mission to be a leader in the development and manufacture of pharma-quality, cannabis API and derivative products. These developments include record shipments in September, product portfolio expansion, and continued progress with Health Canada regarding its Controlled Substances Dealers License application.

Record September Shipments
Adastra shipped 68,272 consumer-packaged units and 20,000g of bulk extract in September compared to 41,571 units in September 2020 , a 64% increase year over year.

Keep reading... Show less

Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that, pursuant to a director’s resolution, the Company will be consolidating its issued and outstanding share capital on the basis of every thirty (30) old Common Shares being consolidated into one (1) new Common Share (the “Share Consolidation”). Any fractional shares remaining after giving effect to the Share Consolidation will be cancelled.

As a result, the outstanding Common Shares of the Company will be reduced to approximately 10,712,484. The Company has no other securities outstanding.

Keep reading... Show less